Teladoc Health Reports Fourth-Quarter and Full-Year 2018 Results

Go back to Teladoc Health Reports Fourth-Quarter and Full-Year 2018 Results

Teladoc (TDOC) PT Lowered to $84 at Oppenheimer

February 28, 2019 9:35 AM EST

Oppenheimer analyst Mohan Naidu lowered the price target on Teladoc (NYSE: TDOC) to $84.00 (from $87.00) while maintaining a Outperform rating.

... More

Teladoc (TDOC) PT Lowered to $70 at Cantor Fitzgerald

February 28, 2019 9:00 AM EST

Cantor Fitzgerald analyst Steven Halper lowered the price target on Teladoc (NYSE: TDOC) to $70.00 (from $83.00) while maintaining a Neutral rating following the company's 4Q earnings report. Revenue was $123M vs. consensus of $120M. Adjusted EBITDA was $5.8M vs. $2.4M a year... More

Teladoc (TDOC) Tops Q4 EPS by 1c, Revenues Beat; Q1 & FY19 EPS Guidance Above Consensus, Q1 & FY19 Revenue Guidance Below Consensus

February 27, 2019 4:05 PM EST

Teladoc (NYSE: TDOC) reported Q4 EPS of ($0.35), $0.01 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $122.74 million versus the consensus estimate of $120 million.

We had an exceptional 2018 with solid performance across all of our key financial and operational metrics, enabling us to enter 2019 with significant momentum. As virtual care becomes mainstream, we are uniquely positioned across all of our channels as the only global comprehensive virtual healthcare solution, said Jason Gorevic, chief executive officer, Teladoc Health. We... More